Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06017869
Other study ID # MNV-010
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 31, 2023
Est. completion date December 2027

Study information

Verified date October 2023
Source Minovia Therapeutics Ltd.
Contact Lea Bensoussan, Msc
Phone + 972 586101291
Email lea@minoviatx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial DNA (mtDNA). While some mitochondrial disorders only affect a single organ (e.g., the eye in Leber hereditary optic neuropathy [LHON]), many involve multiple organs. Mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease. Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.


Recruitment information / eligibility

Status Recruiting
Enrollment 5
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: 1. Male or female participants aged from 1 to 18 years old. 2. Diagnosis of Pearson Syndrome 3. Body weight = 10 kg. 4. Participant has anemia and/or thrombocytopenia, and/or leukopenia and/or blood transfusion dependent (receives blood transfusions every 6 weeks or less). 5. Participant is medically able to undergo the study interventions, as determined by the investigator. 6. Participant's living parent(s) and/or legal guardian(s) able to understand and provide voluntary written informed consent. Exclusion Criteria: 1. History of infection with HIV-1, HIV-2, and HTLV I/II. 2. Current active infection with HBV (including HBcore and HBsAg positive), HCV, HTLV I/II, Treponema Pallidum and HIV I-II 3. Participant has been diagnosed with Myelodysplastic Syndrome, by FISH and/or karyotype. 4. Participant is unable to undergo leukapheresis. 5. Total number of CD34+ cells collected is lower than 20x106 cells 6. Participant has known hypersensitivity to murine proteins or iron-dextran. 7. Participant has chronic severe infection. 8. Participant has disease or condition that may risk the participant or interfere with the ability to interpret the study results. 9. History of malignancy 10. History of treatment with gene therapy, bone marrow or allogeneic cord blood transplantation. 11. Currently participating in another clinical trial, or participation in another clinical trial within 1 year prior to study enrollment. 12. In the opinion of the Investigator, the participant is unsuitable for participating in the study for any reason.

Study Design


Intervention

Biological:
MNV-201
Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.

Locations

Country Name City State
Israel Sheba Medical Center Ramat Gan

Sponsors (1)

Lead Sponsor Collaborator
Minovia Therapeutics Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of treatment-related adverse events Occurrence of treatment-related adverse events as assessed by CTCAE v5.0 following MNV-201 infusion. 12 months post treatment.
Secondary Change in Quality of Life (QoL) questionnaire IPMDS (International Pediatric Mitochondrial Disease Scale) scores, since Baseline and during a follow up period of 3-, 6- or 12-months post treatment. The score is expressed as the percentage of items which were feasible to perform. The lower the score, the better is the child performance. The minimum score is 0% and the maximum score is 100%. 3, 6 or 12 months post treatment.
Secondary Assessment of frequency of hospitalizations Change in frequency of hospitalization during the 12 months after treatment compared to the 6 months period before treatment. 12 months post treatment
Secondary Assessment of lengths of hospitalizations Change in lengths of hospitalization during the 12 months after treatment compared to the 6 months period before treatment. 12 months post treatment
Secondary Change in Anemia Change since Baseline in anemia during a follow up period of 3, 6 or 12 months post treatment measured by CBC. 3, 6 or 12 months post treatment
Secondary Change in thrombocytopenia Changes since baseline in thrombocytopenia during a follow up period of 3, 6 or 12 months post treatment measured by Complete Blood Count. 3, 6 or 12 months post treatment
Secondary Changes in leukopenia during a follow up period of 12 months post treatment Changes since baseline in leukopenia during a follow up period of 3, 6 or 12 months post treatment measured by Complete Blood Count. 3, 6 or 12 months post treatment
Secondary Changes in frequency of blood transfusions during a follow up period of 12 months post treatment. Change in frequency of blood transfusions during a follow up period of 3-, 6- or 12-months post treatment compared to the 6 months period before treatment. 3, 6 or 12 months post treatment
See also
  Status Clinical Trial Phase
Completed NCT03388528 - Low Residue Diet Study in Mitochondrial Disease N/A
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Completed NCT03678740 - Diagnostic Odyssey Survey 2
Recruiting NCT06051448 - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Phase 1/Phase 2
Completed NCT02909400 - The KHENERGY Study Phase 2
Completed NCT02398201 - A Study of Bezafibrate in Mitochondrial Myopathy Phase 2
Completed NCT03857880 - Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
Not yet recruiting NCT06450964 - Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
Completed NCT04165239 - The KHENERGYZE Study Phase 2
Completed NCT02284334 - Glycemic Index in Mitochondrial Disease
Recruiting NCT06080568 - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting NCT06080581 - Mitochondrial Dysfunctions Driving Insulin Resistance
Recruiting NCT04802707 - Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome Phase 2
Completed NCT04594590 - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Completed NCT04580979 - Natural History Study of FDXR Mutation-related Mitochondriopathy
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Recruiting NCT04113447 - Mitochondrial Donation: An 18 Month Outcome Study.
Enrolling by invitation NCT04734626 - CrCest Study in Primary Mitochondrial Disease
Completed NCT03832218 - Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies N/A
Terminated NCT02473445 - A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Phase 2